279
Participants
Start Date
December 16, 2017
Primary Completion Date
July 7, 2022
Study Completion Date
March 30, 2029
Talquetamab
Participants will receive IV infusion or SC injection of Talquetamab.
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liège
Mount Sinai Medical Center, New York
Hosp Univ Fund Jimenez Diaz, Madrid
Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcón
Clinica Univ. de Navarra, Pamplona
University of Alabama Birmingham, Birmingham
Hosp Clinico Univ de Salamanca, Salamanca
Tennessee Oncology, Nashville
University of Colorado Cancer Center, Aurora
City of Hope, Duarte
VU Medisch Centrum, Amsterdam
UMCU, Utrecht
Hosp. Univ. Germans Trias I Pujol, Badalona
Janssen Research & Development, LLC
INDUSTRY